{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:41:35Z","timestamp":1787002895957,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Programmed death-ligand 1 is a glycoprotein expressed on antigen presenting cells, hepatocytes, and tumors which upon interaction with programmed death-1, results in inhibition of antigen-specific T cell responses. Here, we report a mechanism of inhibiting programmed death-ligand 1 through small molecule-induced dimerization and internalization. This represents a mechanism of checkpoint inhibition, which differentiates from anti-programmed death-ligand 1 antibodies which function through molecular disruption of the programmed death 1 interaction. Testing of programmed death ligand 1 small molecule inhibition in a humanized mouse model of colorectal cancer results in a significant reduction in tumor size and promotes T cell proliferation. In addition, antigen-specific T and B cell responses from patients with chronic hepatitis B infection are significantly elevated upon programmed death ligand 1 small molecule inhibitor treatment. Taken together, these data identify a mechanism of small molecule-induced programmed death ligand 1 internalization with potential therapeutic implications in oncology and chronic viral infections.<\/jats:p>","DOI":"10.1038\/s41467-021-21410-1","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T06:06:57Z","timestamp":1613974017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-7780","authenticated-orcid":false,"given":"Jang-June","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily P.","family":"Thi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Harasym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Iott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Kadhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-3482","authenticated-orcid":false,"given":"Jin Hyang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C. H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duyan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna S.","family":"Paratala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-1062","authenticated-orcid":false,"given":"Andre","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodharan","family":"Lakshminarasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Suto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Rijnbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-0440","authenticated-orcid":false,"given":"Chris B.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"21410_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27, 195\u2013201 (2006).","journal-title":"Trends Immunol."},{"key":"21410_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365\u20131369 (1999).","journal-title":"Nat. Med."},{"key":"21410_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"21410_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"21410_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura, H. et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27, 464\u2013472 (2013).","journal-title":"Leukemia"},{"key":"21410_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","volume":"116","author":"A Kondo","year":"2010","unstructured":"Kondo, A. et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 116, 1124\u20131131 (2010).","journal-title":"Blood"},{"key":"21410_CR7","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto, R. et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111, 3220\u20133224 (2008).","journal-title":"Blood"},{"key":"21410_CR8","unstructured":"Chupak, L. S. et al. Compounds useful as Immunomodulators. US patent US20150291549 (2015)."},{"key":"21410_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"21410_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"21410_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"21410_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134\u2013144 (2013).","journal-title":"N. Engl. J. Med."},{"key":"21410_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"21410_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine, J. & Taube, J. M. PD-1\/PD-L1 inhibitors. Curr. Opin. Pharm. 23, 32\u201338 (2015).","journal-title":"Curr. Opin. Pharm."},{"key":"21410_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13354","volume":"7","author":"JY Lee","year":"2016","unstructured":"Lee, J. Y. et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Commun. 7, 13354 (2016).","journal-title":"Nat. Commun."},{"key":"21410_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06002-8","volume":"7","author":"HT Lee","year":"2017","unstructured":"Lee, H. T. et al. Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep. 7, 5532 (2017).","journal-title":"Sci. Rep."},{"key":"21410_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","volume":"9","author":"S Tan","year":"2018","unstructured":"Tan, S. et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell 9, 135\u2013139 (2018).","journal-title":"Protein Cell"},{"key":"21410_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/cr.2016.102","volume":"27","author":"K Liu","year":"2017","unstructured":"Liu, K. et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 27, 151\u2013153 (2017).","journal-title":"Cell Res."},{"key":"21410_CR19","doi-asserted-by":"publisher","first-page":"90215","DOI":"10.18632\/oncotarget.21652","volume":"8","author":"F Zhang","year":"2017","unstructured":"Zhang, F. et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 8, 90215\u201390224 (2017).","journal-title":"Oncotarget"},{"key":"21410_CR20","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1002\/anie.201710407","volume":"57","author":"M Konstantinidou","year":"2018","unstructured":"Konstantinidou, M., Zarganes-Tzitzikas, T., Magiera-Mularz, K., Holak, T. A. & Domling, A. Immune checkpoint PD-1\/PD-L1: is there life beyond antibodies? Angew. Chem. Int. Ed. Engl. 57, 4840\u20134848 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"21410_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2174\/1568026618666180531092503","volume":"18","author":"D Bojadzic","year":"2018","unstructured":"Bojadzic, D. & Buchwald, P. Toward small-molecule inhibition of protein-protein interactions: general aspects and recent progress in targeting costimulatory and coinhibitory (immune checkpoint) interactions. Curr. Top. Med. Chem. 18, 674\u2013699 (2018).","journal-title":"Curr. Top. Med. Chem."},{"key":"21410_CR22","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","volume":"62","author":"S Basu","year":"2019","unstructured":"Basu, S. et al. Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein-protein interaction. J. Med. Chem. 62, 7250\u20137263 (2019).","journal-title":"J. Med. Chem."},{"key":"21410_CR23","doi-asserted-by":"publisher","first-page":"30323","DOI":"10.18632\/oncotarget.8730","volume":"7","author":"KM Zak","year":"2016","unstructured":"Zak, K. M. et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7, 30323\u201330335 (2016).","journal-title":"Oncotarget"},{"key":"21410_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau, J. et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat. Commun. 8, 14572 (2017).","journal-title":"Nat. Commun."},{"key":"21410_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep42687","volume":"7","author":"A Huang","year":"2017","unstructured":"Huang, A. et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci. Rep. 7, 42687 (2017).","journal-title":"Sci. Rep."},{"key":"21410_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s42003-019-0642-9","volume":"2","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Commun. Biol. 2, 392 (2019).","journal-title":"Commun. Biol."},{"key":"21410_CR27","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. A novel anti-PD-L1 vaccine for cancer immunotherapy and immunoprevention. Cancers (Basel) 11, 1909 (2019).","DOI":"10.3390\/cancers11121909"},{"key":"21410_CR28","doi-asserted-by":"publisher","first-page":"e0161779","DOI":"10.1371\/journal.pone.0161779","volume":"11","author":"MJ Selby","year":"2016","unstructured":"Selby, M. J. et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS ONE 11, e0161779 (2016).","journal-title":"PLoS ONE"},{"key":"21410_CR29","doi-asserted-by":"publisher","first-page":"e1294299","DOI":"10.1080\/2162402X.2017.1294299","volume":"6","author":"JW Kleinovink","year":"2017","unstructured":"Kleinovink, J. W. et al. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology 6, e1294299 (2017).","journal-title":"Oncoimmunology"},{"key":"21410_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J. Clin. Investig. 128, 580\u2013588 (2018).","journal-title":"J. Clin. Investig."},{"key":"21410_CR31","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Investig. 128, 4573\u20134587 (2018).","journal-title":"J. Clin. Investig."},{"key":"21410_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"21410_CR33","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","volume":"143","author":"P Fisicaro","year":"2012","unstructured":"Fisicaro, P. et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143, 1576\u20131585 e1574 (2012).","journal-title":"Gastroenterology"},{"key":"21410_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature07662","volume":"458","author":"V Velu","year":"2009","unstructured":"Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206\u2013210 (2009).","journal-title":"Nature"},{"key":"21410_CR35","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1097\/QAD.0000000000001217","volume":"30","author":"AL Gill","year":"2016","unstructured":"Gill, A. L. et al. Programed death-1\/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). AIDS 30, 2487\u20132493 (2016).","journal-title":"AIDS"},{"key":"21410_CR36","doi-asserted-by":"publisher","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","volume":"8","author":"D Gardiner","year":"2013","unstructured":"Gardiner, D. et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 8, e63818 (2013).","journal-title":"PLoS ONE"},{"key":"21410_CR37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane, E. et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J. Hepatol. 71, 900\u2013907 (2019).","journal-title":"J. Hepatol."},{"key":"21410_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00281-017-0641-1","volume":"39","author":"M Hong","year":"2017","unstructured":"Hong, M. & Bertoletti, A. Tolerance and immunity to pathogens in early life: insights from HBV infection. Semin. Immunopathol. 39, 643\u2013652 (2017).","journal-title":"Semin. Immunopathol."},{"key":"21410_CR39","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215\u20134225 (2007).","journal-title":"J. Virol."},{"key":"21410_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2893.2009.01172.x","volume":"17","author":"T Watanabe","year":"2010","unstructured":"Watanabe, T., Bertoletti, A. & Tanoto, T. A. PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J. Viral Hepat. 17, 453\u2013458 (2010).","journal-title":"J. Viral Hepat."},{"key":"21410_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846\u2013856 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"21410_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrm908","volume":"3","author":"KL Pierce","year":"2002","unstructured":"Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639\u2013650 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"21410_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ceb.2015.05.005","volume":"35","author":"R Irannejad","year":"2015","unstructured":"Irannejad, R., Tsvetanova, N. G., Lobingier, B. T. & von Zastrow, M. Effects of endocytosis on receptor-mediated signaling. Curr. Opin. Cell Biol. 35, 137\u2013143 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"21410_CR44","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2016","unstructured":"Park, J. J. et al. Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150, 684\u2013695 e685 (2016).","journal-title":"Gastroenterology"},{"key":"21410_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561\u2013584 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21410_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"21410_CR47","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","volume":"25","author":"KM Zak","year":"2017","unstructured":"Zak, K. M. et al. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2. Structure 25, 1163\u20131174 (2017).","journal-title":"Structure"},{"key":"21410_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"21410_CR49","doi-asserted-by":"crossref","unstructured":"Lee, H. T., Lee, S. H. & Heo, Y. S. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules 24, 1190 (2019).","DOI":"10.3390\/molecules24061190"},{"key":"21410_CR50","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3389\/fimmu.2018.02569","volume":"9","author":"A Saeidi","year":"2018","unstructured":"Saeidi, A. et al. T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front. Immunol. 9, 2569 (2018).","journal-title":"Front. Immunol."},{"key":"21410_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"21410_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1934-z","volume":"18","author":"CT Rueden","year":"2017","unstructured":"Rueden, C. T. et al. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18, 529 (2017).","journal-title":"BMC Bioinformatics"},{"key":"21410_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/jhep.2003.50103","volume":"37","author":"K Sugimoto","year":"2003","unstructured":"Sugimoto, K. et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37, 590\u2013599 (2003).","journal-title":"Hepatology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21410-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:03:40Z","timestamp":1669961020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21410"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21410-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1222"}}